A promising new treatment for small-cell lung cancer (SCLC) has been identified by researchers at Purdue University. The drug, Supinoxin (also known as RX-5902), targets a protein called DDX5, which plays a crucial role in the rapid growth of SCLC cells. By inhibiting DDX5, Supinoxin disrupts the cancer cells’ energy production, leading to reduced tumor growth in laboratory and animal models. This approach offers a potential new avenue for treating SCLC, a particularly aggressive form of lung cancer with limited treatment options.
Supinoxin’s mechanism of action involves interfering with oxidative phosphorylation, a process by which cells generate energy. Unlike many cancer cells that rely on glycolysis, SCLC cells depend on oxidative phosphorylation for survival. By targeting this pathway, Supinoxin effectively starves the cancer cells of energy. The researchers suggest that combining Supinoxin with other therapies could enhance its effectiveness and potentially lead to more successful treatments for SCLC patients. Click for More Details
